On July 7, 2016 Accurexa Inc. (the "Company") (ACXA), a biotechnology company focused on the development of novel neurological therapies to be directly delivered into the brain,reported that it filed a new patent application related to its proprietary formulation used in its ACX-31 program (Press release, Accurexa, JUL 7, 2016, View Source [SID1234516519]). Accurexa is developing its ACX-31 program for the local delivery of temozolomide as adjunctive therapy to BCNU, both chemotherapeutics, in the treatment of brain tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are proud that we as an emerging company have the intellectual capability in-house to create new technologies for our brain cancer program. This is our first patent application that we believe has the potential to further protect our brain cancer program in addition to the patent that we licensed from Prof. Brem and his co-inventors at Johns Hopkins University last year. This is our first step of adding internally created technologies to our model of in-licensing of assets and growing our company’s capabilities and assets," said Dr. George Yu, Accurexa’s President & CEO.